Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

May 1, 2026

Study Completion Date

May 1, 2030

Conditions
SCLCMaintenance Treatment
Interventions
DRUG

Toripalimab plus Anlotinib

For patients who did not progress after standard chemotherapy, toripalimab plus anlotinib maintenance therapy was used

DRUG

Toripalimab

For patients who did not progress after standard chemotherapy+toripalimab, toripalimab maintenance therapy was used

All Listed Sponsors
lead

Taizhou Hospital

OTHER